SB203580 and SB202190, pyridinyl imidazoles that selectively inhibit p38 mitogen-activated protein (MAP) kinase, are widely utilized to assess the physiological roles of p38. Here, we demonstrate that treatment of 3T3-L1 fibroblasts with these p38 MAP kinase inhibitors prevents their differentiation into adipocytes as judged by an absence of lipid accumulation, a lack of expression of adipocyte-specific genes, and a fibroblastic morphological appearance. In 3T3-L1 fibroblasts and developing adipocytes, p38 is active. p38 activity decreases dramatically during later stages of differentiation. In accordance with the time course of p38 activity, p38 inhibitor treatment during only the early stages of differentiation is sufficient to block adipogenesis. In addition, we constructed a 3T3-L1 cell line harboring an inducible dominant negative p38 mutant. The induction of this dominant negative mutant of p38 prevents adipocyte differentiation. Thus, it is likely that the antiadipogenic activity of SB203580 and SB202190 is indeed due to inhibition of p38 MAP kinase.This study points out that CCAAT/enhancer-binding protein  (C/EBP), a transcription factor critical for the initial stages of 3T3-L1 adipogenesis, bears a consensus site for p38 phosphorylation and serves as a substrate for p38 MAP kinase in vitro. Although the induction of C/EBP is not significantly altered in the presence of the p38 inhibitor, the amount of in vivo phosphorylated C/EBP is reduced by SB203580. The transcriptional induction of PPAR␥, a gene whose expression is induced by C/EBP, and a factor critically involved in terminal differentiation of adipocytes, is impaired in the presence of p38 inhibitors. Thus, transcription factors such as C/EBP that promote adipocyte differentiation may be p38 targets during adipogenesis. Collectively, the data in this study suggest that p38 MAP kinase activity is important for proper 3T3-L1 differentiation.SB203580 and SB202190 are highly specific inhibitors of p38 MAP 1 kinase and are widely utilized as tools to probe p38 MAP kinase function in vitro and in vivo (1-5). They are extremely specific, as SB203580 has no inhibitory activity on all kinases tested in vitro, including the other MAP kinases, at concentrations greater than 10-fold the concentration used in our treatment of 3T3-L1 cells (6). In addition, the human homolog of p38 MAP kinase was discovered because it was specifically photoaffinity-labeled by a derivative of SB202190. This compound inhibits LPS-stimulated IL-1 and TNF␣ production, and p38 is its molecular target (7). Recently, a crystal structure of p38 in complex with SB203580 revealed that the inhibitor binds within the ATP pocket of the kinase (8, 9). Single amino acid substitutions within the ATP binding pocket of p38 alter the sensitivity of p38 to the inhibitors (10) and offer an explanation for the specificity of this class of inhibitors.To date, three groups of MAP kinases have been identified in mammalian cells: 1) extracellular signal-regulated kinases that are also referred to...